Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Lung Cancer

    Boston, MA

    Search
    Lung Cancer
    Boston, MA
    Show Map
    Map View
    Boston, MA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      137 Lung Cancer Trials near Boston, MA

      Power is an online platform that helps thousands of Lung Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Selumetinib + Docetaxel for Lung Cancer

      Boston, Massachusetts
      The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor mutations of KRAS. This study will also assess the PK, safety, patient reported outcomes (PRO) and tolerability profile of the selumetinib/docetaxel combination, compared to placebo in combination with docetaxel
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Small Cell Lung Cancer, Others
      Must Not Be Taking:MEK Inhibitors, Docetaxel

      510 Participants Needed

      Radiation + Chemotherapy for Small Cell Lung Cancer

      Brighton, Massachusetts
      Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Nursing, Prior Radiotherapy, Others
      Must Be Taking:Carboplatin, Cisplatin, Etoposide

      731 Participants Needed

      Surgical Procedures for Early-Stage Lung Cancer

      Boston, Massachusetts
      RATIONALE: Wedge resection or segmentectomy may be less invasive types of surgery than lobectomy for non-small cell lung cancer and may have fewer side effects and improve recovery. It is not yet known whether wedge resection or segmentectomy are more effective than lobectomy in treating stage IA non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying different types of surgery to compare how well they work in treating patients with stage IA non-small cell lung cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Prior Malignancy, Chemotherapy, Radiation, Others

      701 Participants Needed

      BMS-986504 + Pembrolizumab + Chemotherapy for Lung Cancer

      Boston, Massachusetts
      The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Spinal Cord Compression, Others

      590 Participants Needed

      Adagrasib + Pembrolizumab for Non-Small Cell Lung Cancer

      Boston, Massachusetts
      This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Autoimmune, Cardiovascular, Bone Marrow, Others
      Must Not Be Taking:QTc Prolonging Drugs, KRAS Inhibitors

      630 Participants Needed

      Dato-DXd + Rilvegostomig for Lung Cancer

      Boston, Massachusetts
      This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:EGFR Mutation, ALK Alteration, ILD, Others

      660 Participants Needed

      Lazertinib + Amivantamab for Non-Small Cell Lung Cancer

      Boston, Massachusetts
      The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Leptomeningeal Disease, ILD, Others
      Must Be Taking:EGFR Inhibitors

      418 Participants Needed

      FMC-376 for Solid Tumors

      Boston, Massachusetts
      The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Leptomeningeal Disease, Carcinomatous Meningitis, Others

      403 Participants Needed

      RAS Inhibitors + Standard Treatments for Lung Cancer

      Boston, Massachusetts
      The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Tumors, Impaired GI Function, Others

      616 Participants Needed

      ELI-002 for Colorectal Cancer

      Boston, Massachusetts
      This trial is testing a new treatment called ELI-002 7P for patients with specific types of cancer. The treatment helps the immune system recognize and attack these cancer cells. ELI-002 7P targets mutations that are common in various cancers and have been studied for their role in tumor growth and resistance to treatments.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Others
      Must Not Be Taking:Immunosuppressive Drugs

      158 Participants Needed

      PT217 for Small Cell Lung Cancer

      Boston, Massachusetts
      This trial is testing a new antibody treatment called PT217 for patients with certain neuroendocrine cancers who haven't responded to usual treatments. PT217 helps the immune system target and destroy cancer cells by attaching to specific proteins on them.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Autoimmune Disease, Untreated Brain Metastases, Others
      Must Not Be Taking:Immunostimulatory Agents, Corticosteroids

      203 Participants Needed

      BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer

      Boston, Massachusetts
      BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Resistant Mutations, Interstitial Lung Disease, Others
      Must Be Taking:EGFR TKIs

      200 Participants Needed

      STK-012 + Pembrolizumab for Cancer

      Boston, Massachusetts
      This trial is testing a new drug called STK-012 alone and with another medication in patients with advanced solid tumors that haven't responded to usual treatments. The aim is to find the right dose and see how well it works.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Recent Radiotherapy, IL-2/IL-15 Therapy, Others
      Must Not Be Taking:Small Molecule Inhibitors

      364 Participants Needed

      Nanoparticle-Enhanced Radiotherapy for Pancreatic Cancer

      Boston, Massachusetts
      This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation therapy (SBRT) in the treatment of pancreatic cancer and lung tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, Prior Radiation, Others
      Must Be Taking:Induction Chemotherapy

      100 Participants Needed

      JDQ443 for Cancer

      Boston, Massachusetts
      This trial is testing a new drug, JDQ443, alone and with two other drugs, in patients with advanced solid tumors. It aims to find the safest dose and see if the combination can effectively reduce tumors.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Cardiac Disease, Photosensitivity, Others

      344 Participants Needed

      Tucatinib + Trastuzumab for HER2-Positive Cancers

      Boston, Massachusetts
      This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant. The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Breast Cancer, Gastric Cancer, CRC, Others
      Must Be Taking:Tucatinib, Trastuzumab

      217 Participants Needed

      Testosterone Gel for Cancer-Related Fatigue

      Boston, Massachusetts
      This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer who report fatigue and have low testosterone levels.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:55+
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Prostate Cancer, Sleep Apnea, Others
      Must Not Be Taking:Anabolic Agents

      230 Participants Needed

      Tepotinib + Osimertinib for Non-Small Cell Lung Cancer

      Boston, Massachusetts
      This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastasis, Impaired Cardiac Function, Others
      Must Be Taking:Osimertinib

      140 Participants Needed

      Osimertinib for Lung Cancer

      Boston, Massachusetts
      This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: \- Osimertinib (Tagrisso)
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:CNS Disease, Heart Disease, Infections, Others
      Must Be Taking:Osimertinib

      30 Participants Needed

      Tisotumab Vedotin for Cancer

      Boston, Massachusetts
      This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Neuroendocrine, Sarcomatoid, Active Bleeding, Others
      Must Not Be Taking:Systemic Steroids

      352 Participants Needed

      Why Other Patients Applied

      "I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

      EQ
      Lung Cancer PatientAge: 70

      "I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

      FR
      Lung Cancer PatientAge: 71

      "I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."

      UM
      Pancreatic Cancer PatientAge: 48

      "My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

      OF
      Cholangiocarcinoma PatientAge: 54

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40
      Match to a Lung Cancer Trial

      Osimertinib + Selumetinib for Lung Cancer

      Boston, Massachusetts
      This research study is studying a combination of two targeted therapies as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The drugs involved in this study are: * Osimertinib (Tagrisso) * Selumetinib
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, CNS Disease, Others
      Must Not Be Taking:CYP3A4 Inhibitors, Vitamin E

      25 Participants Needed

      Alectinib + Cobimetinib for Lung Cancer

      Boston, Massachusetts
      This research study is studying a drug combination as a possible treatment for anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. The drugs involved in this study are: * Alectinib * Cobimetinib
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, HIV, Heart Failure, Others
      Must Be Taking:Alectinib

      16 Participants Needed

      BMS-986504 for Non-Small Cell Lung Cancer

      Boston, Massachusetts
      The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Active Brain Metastases, Gastrointestinal Disease, Others
      Must Not Be Taking:PRMT5, MAT2A Inhibitors

      130 Participants Needed

      Amivantamab Combinations for Non-Small Cell Lung Cancer

      Boston, Massachusetts
      The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Active ILD, Major Surgery, Uncontrolled Pain, Others

      480 Participants Needed

      CoREST Inhibitor + Anti-PD-1 Therapy for Solid Cancers

      Boston, Massachusetts
      This trial is testing a new drug, TNG260, combined with an existing cancer treatment, pembrolizumab, in patients with advanced solid tumors that have an STK11 mutation. TNG260 aims to block proteins that help cancer grow, while pembrolizumab boosts the immune system to fight the cancer. Pembrolizumab has been shown to be an effective and safe therapeutic option for various advanced cancers, including endometrial cancer and melanoma. The study will determine the best dose, safety, and effectiveness of this combination.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Active Malignancy, CNS Metastases, Others

      126 Participants Needed

      I-DXd for Small Cell Lung Cancer

      Boston, Massachusetts
      This trial tests a new drug, ifinatamab deruxtecan (I-DXd), on patients with a specific type of lung cancer who have not responded to other treatments. The drug aims to target and kill cancer cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Cardiovascular Disease, ILD, Others
      Must Not Be Taking:Steroids, Anticonvulsants

      187 Participants Needed

      AZD8205 for Endometrial Cancer

      Boston, Massachusetts
      This trial is testing a new drug called AZD8205 to see if it can help treat advanced or spreading solid tumors. The study includes patients whose cancer is advanced or has spread and may not respond to current treatments. AZD8205 might work by stopping or slowing down the growth of cancer cells.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Active Infection, Cardiac Issues, Others
      Must Not Be Taking:Nitrosourea, Mitomycin C, Others

      370 Participants Needed

      Combination Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

      Boston, Massachusetts
      The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:EGFR Mutations, ALK Translocations, Autoimmune Disorders, Others
      Must Not Be Taking:Immunosuppressants, Chemotherapy, Biologics, Others

      630 Participants Needed

      Patritumab Deruxtecan for Non-Small Cell Lung Cancer

      Boston, Massachusetts
      This trial is testing a new drug called patritumab deruxtecan for patients with advanced lung cancer who have specific genetic mutations and have not responded to other treatments. The drug targets cancer cells specifically and delivers chemotherapy directly to them.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Small Cell Disease, Interstitial Lung Disease, Severe Respiratory Compromise, Brain Metastases, Others
      Must Be Taking:EGFR TKIs

      277 Participants Needed

      DS-1062a for Lung Cancer

      Boston, Massachusetts
      This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiovascular Disease, ILD, Others
      Must Be Taking:Targeted Therapy

      137 Participants Needed

      12345

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials in Massachusetts

      Anxiety Clinical Trials in Massachusetts

      Schizophrenia Clinical Trials in Massachusetts

      ADHD Clinical Trials in Massachusetts

      Bipolar Disorder Clinical Trials in Massachusetts

      Multiple Sclerosis Clinical Trials in Massachusetts

      Autism Clinical Trials in Massachusetts

      Treatment Resistant Depression Clinical Trials in Massachusetts

      Borderline Personality Disorder Clinical Trials in Massachusetts

      Social Anxiety Disorder Clinical Trials in Massachusetts

      Parkinson's Disease Clinical Trials in Massachusetts

      Alzheimer's Disease Clinical Trials in Massachusetts

      By Location

      Clinical Trials near Boston, MA

      Clinical Trials near Worcester, MA

      Clinical Trials near Springfield, MA

      Clinical Trials near Burlington, MA

      Clinical Trials near Fall River, MA

      Clinical Trials near Cambridge, MA

      Clinical Trials near North Dartmouth, MA

      Clinical Trials near Newton, MA

      Clinical Trials near Waltham, MA

      Clinical Trials near Watertown, MA

      Clinical Trials near Belmont, MA

      Clinical Trials near Brockton, MA

      Other People Viewed

      By Subject

      Top Colorectal Cancer Clinical Trials near Boston, MA

      Top Breast Cancer Clinical Trials near Boston, MA

      Top Prostate Cancer Clinical Trials near Boston, MA

      Top Clinical Trials near Boston, MA

      Top Clinical Trials near Boston, MA

      Top Depression Clinical Trials near Boston, MA

      Top Osteoarthritis Clinical Trials near Boston, MA

      Top Osteoporosis Clinical Trials near Boston, MA

      Top Weight Loss Clinical Trials near Boston, MA

      Top Obsessive Compulsive Disorder Ocd Clinical Trials near Boston, MA

      Top Clinical Trials near Jamaica Plain, MA

      Top Clinical Trials near Attleboro, MA

      By Trial

      Serplulimab + Chemotherapy for Small Cell Lung Cancer

      MyLungHealth for Lung Cancer Screening

      Binimetinib + Pembrolizumab for Non-Small Cell Lung Cancer

      Synapse 3D + IC-Green for Early-Stage Lung Cancer

      Healthy Diet for High Blood Pressure

      Zipalertinib for Non-Small Cell Lung Cancer

      Pevonedistat + Chemotherapy for Non-Small Cell Lung Cancer

      REGN5093 for Lung Cancer

      Stereotactic Radiotherapy for Lung Cancer

      L-NMMA + Pembrolizumab for Cancer

      EBUS-TBNA Diagnostic Procedure for Early-Stage Lung Cancer

      Patritumab Deruxtecan for Non-Small Cell Lung Cancer

      Related Searches

      Top Lung-cancer Clinical Trials near Anaheim, CA

      Top Lung-cancer Clinical Trials near Long Beach, CA

      Top Lung-cancer Clinical Trials near Dallas, TX

      Top Lung-cancer Clinical Trials near Las Vegas, NV

      Top Lung-cancer Clinical Trials near Columbia, SC

      Top Lung-cancer Clinical Trials near Cincinnati, OH

      Top Lung-cancer Clinical Trials near Philadelphia, PA

      Top Lung-cancer Clinical Trials near Phoenix, AZ

      Top Lung-cancer Clinical Trials near Raleigh, NC

      Tislelizumab + Investigational Agents for Head and Neck Cancer

      Apalutamide for Prostate Cancer

      Mindfulness for Alzheimer's Disease

      Frequently Asked Questions

      How much do Lung Cancer clinical trials in Boston, MA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Lung Cancer clinical trials in Boston, MA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Lung Cancer trials in Boston, MA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Boston, MA for Lung Cancer is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Boston, MA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Lung Cancer medical study in Boston, MA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Lung Cancer clinical trials in Boston, MA?

      Most recently, we added Zongertinib for Lung Cancer, BMS-986504 + Pembrolizumab + Chemotherapy for Lung Cancer and Izalontamab Brengitecan vs Platinum-Pemetrexed for Lung Cancer to the Power online platform.